<DOC>
	<DOCNO>NCT00784979</DOCNO>
	<brief_summary>The purpose study offer Panel Reactive Antibodies [ PRA ] reduction treatment high responder renal transplant patient otherwise may never compatible potential organ donor . PRA reduction offer following phase : 1 . Immunological Testing 2 . Transplant Nephrectomy 3 . Pharmacologic Therapy 4 . Plasmapheresis 5 . Transplant</brief_summary>
	<brief_title>Panel Reactive Antibody ( PRA ) Reduction Sensitized Patients Awaiting Renal Transplantation</brief_title>
	<detailed_description>Patients high level preform antibody ( panel reactive antibody [ PRA ] ) donor antigen make identification suitable donor difficult . For transplant center , 20-35 % patient wait kidney transplant comprise challenge group . These patient wait time five year many incompatible cross-matches potential organ donor .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Renal transplant recipient potential living donor incompatible ( T &amp; /or Bcell locus ) due recipient high PRA MHC antibody PRA great equal 20 % within last twelve month Recipient donor accept potential candidate LifeLink Healthcare Renal Transplant Committee Patients know allergy CytoGam ( R ) , Cellcept , Rapamycin Patients receive IVIG CytoGam ( R ) cause prior protocol process ABO incompatibility Patients capable follow treatment various reason determine treat physician Any potential recipient pregnant become pregnant Exclusion Plasmapheresis : know allergy ethylene oxide natural rubber latex . Exclusion Plasmapheresis : Intake ACEinhibitor Angtiotensiinreceptor blocker last 24 hour prior plasma exchange</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
	<keyword>PRA</keyword>
</DOC>